Nautilus Biotechnology (NASDAQ:NAUT – Get Rating) is one of 42 publicly-traded companies in the “Analytical instruments” industry, but how does it compare to its rivals? We will compare Nautilus Biotechnology to related companies based on the strength of its profitability, earnings, analyst recommendations, valuation, dividends, risk and institutional ownership.
Earnings and Valuation
This table compares Nautilus Biotechnology and its rivals top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Nautilus Biotechnology | N/A | -$50.31 million | -6.53 |
| Nautilus Biotechnology Competitors | $1.19 billion | $356.47 million | -26.21 |
Nautilus Biotechnology’s rivals have higher revenue and earnings than Nautilus Biotechnology. Nautilus Biotechnology is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Institutional and Insider Ownership
47.9% of Nautilus Biotechnology shares are owned by institutional investors. Comparatively, 61.9% of shares of all “Analytical instruments” companies are owned by institutional investors. 13.0% of shares of all “Analytical instruments” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Nautilus Biotechnology and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nautilus Biotechnology | N/A | -15.57% | -14.77% |
| Nautilus Biotechnology Competitors | -232.11% | 7.13% | -10.99% |
Analyst Ratings
This is a summary of recent ratings for Nautilus Biotechnology and its rivals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nautilus Biotechnology | 0 | 2 | 2 | 0 | 2.50 |
| Nautilus Biotechnology Competitors | 324 | 1330 | 1829 | 58 | 2.46 |
Nautilus Biotechnology presently has a consensus target price of $8.67, suggesting a potential upside of 132.97%. As a group, “Analytical instruments” companies have a potential upside of 32.63%. Given Nautilus Biotechnology’s stronger consensus rating and higher probable upside, analysts clearly believe Nautilus Biotechnology is more favorable than its rivals.
Summary
Nautilus Biotechnology rivals beat Nautilus Biotechnology on 8 of the 12 factors compared.
Nautilus Biotechnology Company Profile (Get Rating)
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.
Want More Great Investing Ideas?
- 3 Stocks to DOUBLE This Year
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 9 “MUST OWN” Growth Stocks
Receive News & Ratings for Nautilus Biotechnology Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Nautilus Biotechnology and related companies with MarketBeat.com’s FREE daily email newsletter.